Roche Holding AG said Monday that a Phase 3 study on its monoclonal antibody drug Tecentriq met the primary endpoint of providing disease-free survival to lung cancer patients.
The Swiss pharmaceutical major said the drug showed a statistically significant improvement in disease-free survival for patients suffering non-small-cell lung cancer after surgery and chemotherapy.
Tecentriq is already approved for five indications for different types of lung cancer in markets around the world, Roche said.